liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
EFFICACY AND SAFETY OF ORAL BACLOFEN IN THE MANAGEMENT OF SPASTICITY: A RATIONALE FOR INTRATHECAL BACLOFEN
Linköping University, Department of Medical and Health Sciences. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Anaesthetics, Operations and Specialty Surgery Center, Department of Rehabilitation Medicine.ORCID iD: 0000-0001-6464-9130
Medtron EMEA Regional Clin Centre, Italy.
Medtron Int Trading Sarl, Switzerland.
2017 (English)In: Journal of Rehabilitation Medicine, ISSN 1650-1977, E-ISSN 1651-2081, Vol. 49, no 3, 193-203 p.Article, review/survey (Refereed) Published
Abstract [en]

Oral baclofen has long been a mainstay in the management of spasticity. This review looks at the clinical evidence for the efficacy and safety of oral baclofen in patients with spasticity of any origin or severity, to determine whether there is a rationale for the use of intrathecal baclofen. Results suggest that oral baclofen may be effective in many patients with spasticity, regardless of the underlying disease or severity, and that it is at least comparable with other antispasmodic agents. However, adverse effects, such as muscle weakness, nausea, somnolence and paraesthesia, are common with oral baclofen, affecting between 25% and 75% of patients, and limiting its usefulness. Intrathecal baclofen may be an effective alternative as the drug is delivered directly into the cerebrospinal fluid, thus bypassing the blood-brain barrier and thereby optimizing the efficacy of baclofen while minimizing drug-related side-effects. Intrathecal baclofen is a viable option in patients who experience intolerable side-effects or who fail to respond to the maximum recommended dose of oral baclofen.

Place, publisher, year, edition, pages
FOUNDATION REHABILITATION INFORMATION , 2017. Vol. 49, no 3, 193-203 p.
Keyword [en]
intrathecal baclofen; oral baclofen; spasticity
National Category
Neurology
Identifiers
URN: urn:nbn:se:liu:diva-136621DOI: 10.2340/16501977-2211ISI: 000398050300001PubMedID: 28233010OAI: oai:DiVA.org:liu-136621DiVA: diva2:1089888
Note

Funding Agencies|Medtronic International Trading Sarl

Available from: 2017-04-21 Created: 2017-04-21 Last updated: 2017-04-21

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Ertzgaard, Per
By organisation
Department of Medical and Health SciencesFaculty of Medicine and Health SciencesDepartment of Rehabilitation Medicine
In the same journal
Journal of Rehabilitation Medicine
Neurology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 36 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf